

Date: January 03, 2026

To,
 Sr. General Manager
 Listing Department
BSE Limited
 Phiroze Jeejeebhoy Towers
 Dalal Street
 Mumbai – 400 001

BSE Scrip Code: 544319

To,
 Sr. General Manager
 Listing Department
National Stock Exchange of India Limited
 Exchange Plaza, C-1, Block G
 Bandra Kurla Complex
 Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Intimation of Board Meeting to be held on Wednesday, January, 7, 2026

Dear Sir/Madam,

Pursuant to Regulation 29 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that a meeting of the Board of Directors ("Board") of Senores Pharmaceuticals Limited (the "Company") is scheduled to be held on Wednesday, January 07, 2026, inter alia, to:

1. consider and evaluate proposals for raising funds by way of issue of convertible warrants on preferential basis to the promoters/promoter group including determination of issue price, in accordance with the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018, as amended, (the "**SEBI ICDR Regulations**") and all other applicable laws, as may be considered appropriate, subject to the approval of the Board of Directors, Shareholders and receipt of such regulatory / statutory approvals as may be required; and
2. transact ancillary and other business matters, as may be decided by the Board.

Further, in this connection, please refer our earlier intimation dated December 25, 2025, whereby, pursuant to the Company's Code of Conduct framed in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended ("the Code"), the Trading Window for dealing in securities of the Company, for persons specified under the Code, was closed from January 01, 2026 till 48 hours after the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025 are approved by the Board of Directors and submitted to Stock Exchanges. Therefore, the trading window is not required to be separately closed for the aforesaid purpose.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
 Company Secretary and Compliance Officer
 ICSI Membership No.: F11464

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
 W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263